Randomised controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major
In conditions requiring repeated blood transfusion or where iron metabolism is abnormal, heart failure may result from accumulation of iron in the heart (cardiac siderosis). Death due to heart failure from cardiac iron overload has accounted for considerable early mortality in β-thalassemia major....
Main Authors: | Arun John Baksi, Dudley J Pennell |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fphar.2014.00217/full |
Similar Items
-
Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia
by: Paul Kirk, et al.
Published: (2017-03-01) -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
by: Emanuele Angelucci, et al.
Published: (2017-03-01) -
Overview of chelation recommendations for thalassaemia and sickle cell disease
by: Banu Kaya
Published: (2014-12-01) -
Body iron status of children and adolescents with transfusion dependent β-thalassaemia: trends of serum ferritin and associations of optimal body iron control
by: Tharindi Suriapperuma, et al.
Published: (2018-08-01) -
Assessment of hepatic and cardiac iron overload in thalassemia patients by magnetic resonance imaging: Our experience in Alexandria University
by: Sara K. Elfawal, et al.
Published: (2018-06-01)